Phenylketonuria Scientific Review Conference: state of the science and future research needs
- PMID: 24667081
- DOI: 10.1016/j.ymgme.2014.02.013
Phenylketonuria Scientific Review Conference: state of the science and future research needs
Abstract
New developments in the treatment and management of phenylketonuria (PKU) as well as advances in molecular testing have emerged since the National Institutes of Health 2000 PKU Consensus Statement was released. An NIH State-of-the-Science Conference was convened in 2012 to address new findings, particularly the use of the medication sapropterin to treat some individuals with PKU, and to develop a research agenda. Prior to the 2012 conference, five working groups of experts and public members met over a 1-year period. The working groups addressed the following: long-term outcomes and management across the lifespan; PKU and pregnancy; diet control and management; pharmacologic interventions; and molecular testing, new technologies, and epidemiologic considerations. In a parallel and independent activity, an Evidence-based Practice Center supported by the Agency for Healthcare Research and Quality conducted a systematic review of adjuvant treatments for PKU; its conclusions were presented at the conference. The conference included the findings of the working groups, panel discussions from industry and international perspectives, and presentations on topics such as emerging treatments for PKU, transitioning to adult care, and the U.S. Food and Drug Administration regulatory perspective. Over 85 experts participated in the conference through information gathering and/or as presenters during the conference, and they reached several important conclusions. The most serious neurological impairments in PKU are preventable with current dietary treatment approaches. However, a variety of more subtle physical, cognitive, and behavioral consequences of even well-controlled PKU are now recognized. The best outcomes in maternal PKU occur when blood phenylalanine (Phe) concentrations are maintained between 120 and 360 μmol/L before and during pregnancy. The dietary management treatment goal for individuals with PKU is a blood Phe concentration between 120 and 360 μmol/L. The use of genotype information in the newborn period may yield valuable insights about the severity of the condition for infants diagnosed before maximal Phe levels are achieved. While emerging and established genotype-phenotype correlations may transform our understanding of PKU, establishing correlations with intellectual outcomes is more challenging. Regarding the use of sapropterin in PKU, there are significant gaps in predicting response to treatment; at least half of those with PKU will have either minimal or no response. A coordinated approach to PKU treatment improves long-term outcomes for those with PKU and facilitates the conduct of research to improve diagnosis and treatment. New drugs that are safe, efficacious, and impact a larger proportion of individuals with PKU are needed. However, it is imperative that treatment guidelines and the decision processes for determining access to treatments be tied to a solid evidence base with rigorous standards for robust and consistent data collection. The process that preceded the PKU State-of-the-Science Conference, the conference itself, and the identification of a research agenda have facilitated the development of clinical practice guidelines by professional organizations and serve as a model for other inborn errors of metabolism.
Keywords: Glycomacropeptide; Hyperphenylalaninemia; Large neutral amino acids; Maternal PKU; Phenylketonuria; Sapropterin.
Copyright © 2014. Published by Elsevier Inc. All rights reserved.
Comment in
-
National Institutes of Health (NIH) review of evidence in phenylalanine hydroxylase deficiency (phenylketonuria) and recommendations/guidelines for therapy from the American College of Medical Genetics (ACMG) and Genetics Metabolic Dietitians International (GMDI).Mol Genet Metab. 2014 Jun;112(2):85-6. doi: 10.1016/j.ymgme.2014.03.005. Epub 2014 Mar 25. Mol Genet Metab. 2014. PMID: 24745849 No abstract available.
Similar articles
-
National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.Pediatrics. 2001 Oct;108(4):972-82. doi: 10.1542/peds.108.4.972. Pediatrics. 2001. PMID: 11581453 Review.
-
International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.Mol Genet Metab. 2019 May;127(1):1-11. doi: 10.1016/j.ymgme.2019.04.004. Epub 2019 Apr 26. Mol Genet Metab. 2019. PMID: 31103398 Review.
-
Metabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.Nutrients. 2021 Sep 6;13(9):3118. doi: 10.3390/nu13093118. Nutrients. 2021. PMID: 34578995 Free PMC article.
-
Phenylketonuria (PKU): screening and management.NIH Consens Statement. 2000 Oct 16-18;17(3):1-33. NIH Consens Statement. 2000. PMID: 11757784 Review.
-
Adjuvant Treatment for Phenylketonuria: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 56 [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. Report No.: 12-EHC130-EF. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. Report No.: 12-EHC130-EF. PMID: 23678512 Free Books & Documents. Review.
Cited by
-
Development and validation of machine-learning models of diet management for hyperphenylalaninemia: a multicenter retrospective study.BMC Med. 2024 Sep 11;22(1):377. doi: 10.1186/s12916-024-03602-w. BMC Med. 2024. PMID: 39256839 Free PMC article.
-
Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials.Pharmaceut Med. 2024 Jul;38(4):261-276. doi: 10.1007/s40290-024-00529-8. Epub 2024 Jul 9. Pharmaceut Med. 2024. PMID: 38977611 Review.
-
The struggle that is phenylketonuria: What do the patients and caregivers suffer from.Medicine (Baltimore). 2024 Jun 21;103(25):e38678. doi: 10.1097/MD.0000000000038678. Medicine (Baltimore). 2024. PMID: 38905389 Free PMC article.
-
Phenylketonuria from the perspectives of patients in Türkiye.Orphanet J Rare Dis. 2024 Feb 20;19(1):78. doi: 10.1186/s13023-024-03079-z. Orphanet J Rare Dis. 2024. PMID: 38378595 Free PMC article.
-
Total choline intake and working memory performance in adults with phenylketonuria.Orphanet J Rare Dis. 2023 Jul 29;18(1):222. doi: 10.1186/s13023-023-02842-y. Orphanet J Rare Dis. 2023. PMID: 37516884 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
